Here, we shed light on the origins of the proposed controversial “SCLC-Y” subtype, making the surprising observation that the majority of SCLC-Y tumor cell lines, on which the classification of SCLC-Y category was largely based, harbour SMARCA4 mutations. Here, SMARCA4 is linked to neoplasm.